We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Gene Found for Early-Onset Obesity

By Biotechdaily staff writers
Posted on 04 Oct 2005
Scientists investigating the genetic differences between DNA samples from around 200 people with early-onset obesity and people with normal weight have found a striking difference between these groups: those with hyperphagia, an overeating disorder, had a high frequency of a gene named COB1 by Myriad Genetics, Inc. More...
(Salt Lake City, UT, USA), which conducted the investigation.

The COB1 gene is the first common genetic mutation to be associated with childhood obesity. Although it was previously known to be involved in the regulation of insulin signaling, it was not known to be linked to hyperphagia. People with early-onset obesity have a markedly increased risk for type 2 diabetes. The COB1 gene has potential as a drug target to treat obese children and may also help diagnose the exact cause of the disease.

The Myriad scientists utilized a novel proprietary technology developed by Myriad to advance traditional positional cloning, the technique used in the 1990s to discover genes such as BRCA1 and BRCA2 genes for breast cancer and ovarian cancer. Certain aspects of COB1's biology are already known. For example, it has a prominent role in the regulation of insulin signaling. Insulin acts on certain neurons to inhibit food intake. Mutations in COB1 may alter this signaling and promote abnormal eating behavior.

The link between COB1 and hyperphagia was discovered with genomic DNA from a large number of people. This DNA was combined in equal amounts into a pool and hybridized to a high-density single nucleotide polymorphism (SNP) array. Each one of the 100,000 different SNPs, representing parts of genes in the human genome, was analyzed for its relative proportion of hybridized DNA and compared to the total amount in the pool. This provides a quantitative frequency of each gene in the disease samples when compared with known controls. When one gene frequency is over- or under-represented by a sufficient margin, a disease association can be proposed. In the case of COB1, the association was highly robust.



Related Links:
Myriad Genetics

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.